Alzamend Neuro

Alzamend Neuro is an Atlanta, Georgia-based clinical-stage biopharmaceutical company developing novel products for neurodegenerative and psychiatric disorders, with a focus on Alzheimer's disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder. Its two lead candidates are AL001, a patented ionic cocrystal that delivers lithium together with salicylate and L-proline and is designed to improve brain delivery and safety relative to conventional lithium, and ALZN002, a patented cell-based therapeutic vaccine intended to restore the immune system's ability to clear the pathology associated with Alzheimer's. The company was incorporated in 2016, listed on Nasdaq in June 2021, and reported positive topline data in March 2026 from a Phase II 'Lithium in Brain' study of AL001 that demonstrated bioequivalence and superior brain delivery across all measured brain regions. It initiated a Phase II trial of AL001 in bipolar disorder in March 2026 in collaboration with Massachusetts General Hospital, and in 2026 its Phase 1/2A lithium neuroimaging data were accepted for presentation at the Neuroscience 2026 annual meeting.